Get the Stockscreener App
3.97
0.25%
-0.010
Senti Biosciences Inc stock is traded at $3.97, with a volume of 188.16K.
It is down -0.25% in the last 24 hours and up +87.26% over the past month.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
See More
Previous Close:
$3.98
Open:
$4.08
24h Volume:
188.16K
Relative Volume:
0.09
Market Cap:
$18.22M
Revenue:
$1.79M
Net Income/Loss:
$-64.45M
P/E Ratio:
-2.4207
EPS:
-1.64
Net Cash Flow:
$-53.32M
1W Performance:
-28.73%
1M Performance:
+87.26%
6M Performance:
+61.84%
1Y Performance:
-5.23%
1-Day Range:
$3.82
$4.29
1-Week Range:
$3.6025
$5.44
52-Week Range:
$1.5201
$16.94
Senti Biosciences Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Inc
Sector
Industry
Phone
(650) 382-3281
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
3.97 | 18.22M | 1.79M | -64.45M | -53.32M | -14.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Stock (SNTI) Latest News
Comparing VectivBio (NASDAQ:VECT) and Senti Biosciences (NASDAQ:SNTI) - Defense World
Senti Biosciences (NASDAQ:SNTI) & BioNTech (NASDAQ:BNTX) Head to Head Review - Defense World
Senti Bio Launches Groundbreaking CAR-NK Cell Therapy Trial for Liver Cancer in China - StockTitan
Cathie Wood's ARK buys Tempus AI stock, sheds Senti Biosciences By Investing.com - Investing.com Nigeria
Cathie Wood's ARK buys Tempus AI stock, sheds Senti Biosciences - Investing.com
Chardan Capital Has Negative Outlook of SNTI FY2024 Earnings - Defense World
Senti Bio price target raised to $12 from $10 at Chardan - Yahoo Finance
Senti Biosciences Skyrockets 400% On Oversubscribed PIPE Deal, Promising Cancer Trial Data: Retail Overjoyed - MSN
Chardan lifts Senti Biosciences stock target on positive trial data By Investing.com - Investing.com Nigeria
Chardan lifts Senti Biosciences stock target on positive trial data - Investing.com
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study - MSN
Senti Biosciences Announces New Employment Inducement Grants - The Manila Times
Senti Biosciences Approves New Employee Stock Options in Latest Inducement Grants - StockTitan
Stock market news: Sharps Technology -34.40%, Senti Biosciences -28.60% among biggest losers during mid day trading - Business Upturn
Stock market news: Exicure -34.53%, Senti Biosciences -23.70% among biggest losers in early trading - Business Upturn
Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202 - Yahoo Finance
Senti Biosciences reports early success in AML trial - The Pharma Letter
Senti Bio appoints new board member and audit chair By Investing.com - Investing.com Canada
Senti Biosciences, Inc. announced that it expects to receive $37.60425 million in funding from Celadon Partners, New Enterprise Associates, Inc., Leaps by Bayer, Nantahala Capital Management, LLC and other investors - Marketscreener.com
Senti Biosciences, Inc. (SNTI) could keep surging and here’s why - BP Journal
Senti Biosciences Advances with Key Financial and Strategic Moves - TipRanks
Stock market news: Senti Biosciences +404.62%, Fossil Group +54.11% among top gainers during mid day trading - Business Upturn
Stock market news: Intel rises 4%,Apple increases 1.08%,Super Micro Computer surges 32.31% - Business Upturn
Stock market news: Senti Biosciences surge by 428.24% while Mondee Holdings plunged by 46.49% during mid day trading - Business Upturn
Why Is Senti Biosciences Stock Surging Over 400% On Monday? - Inkl
Senti Bio Shares Catapult After $37.6M Private Placement, Positive Phase 1 Trial - MarketWatch
Stock market today: Senti Biosciences +412.04%, NovoCure +31.89% among top gainers in early trading - Business Upturn
Stock market today: Senti Biosciences surged 344.42% while Mondee Holdings declined by 31.33% in early trading - Business Upturn
SNTI Stock Soars to 52-Week High, Reaching $7.7 - Investing.com
Senti Biosciences stock soars 200% on positive trial data By Investing.com - Investing.com Nigeria
SNTI Stock Soars to 52-Week High, Reaching $7.7 By Investing.com - Investing.com UK
Senti Biosciences stock soars 200% on positive trial data - Investing.com
U.S. STOCKS Intel, PTC Therapeutics, Senti Bio - XM
Senti Biosciences’ SENTI-202 Shows Promising Phase 1 Results - TipRanks
Senti Bio announces oversubscribed $37.6M private placement financing - TipRanks
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing - The Manila Times
Senti Bio appoints Fran Schulz to board of directors - TipRanks
Senti Bio appoints new board member and audit chair - Investing.com
Senti Bio Appoints Fran Schulz to Board of Directors - The Manila Times
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML - The Manila Times
Senti Biosciences Secures $37.6M Private Placement for Cancer Therapy Development - StockTitan
Senti Bio Appoints Life Sciences Finance Veteran Fran Schulz to Board, Names Audit Chair - StockTitan
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Senti Biosciences Faces Financial Challenges Amid Strategic Focus - TipRanks
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights - The Manila Times
Senti Biosciences Inc (SNTI) Quarterly 10-Q Report - Quartzy
Senti Bio Reports $28.9M Q3 Loss, Advances Cancer Drug Trial Amid Cost Cuts | SNTI Stock News - StockTitan
Intel says it lowered stakes in Astera Labs, Joby Aviation, Senti Biosciences - MSN
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Palantir Technologies Inc (PLTR-Q) QuotePress Release - The Globe and Mail
Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update - MarketBeat
Senti Biosciences Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):